Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review

Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review

Background: To assess the cost-effectiveness of sacubitril/valsartan compared with enalapril in patients with heart failure with reduced ejection (HFrEF). Methods: A systematic literature search was conducted searching in major electronic databases from inception to January 1, 2021. All relevant...

Full description

Bibliographic Details
Main Authors:	Aziz Rezapour, Samad Azari, Jalal Arabloo, Pirhossein Kolivand, Masoud Behzadifar, Negar Omidi, Ali Sarabi Asiabar, Peyman Saberian, Hamid Pourasghari, Nicola luigi Bragazzi, Mehdi Mehrani, Shayan Shahi, Masih Tajdini
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2022-10-01
Series:	Journal of Tehran University Heart Center
Subjects:	Cost-effectiveness analysis Sacubitril-valsartan Heart Failure; epidemiology Heart Failure; therapy Systematic review
Online Access:	https://jthc.tums.ac.ir/index.php/jthc/article/view/1752

Similar Items

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia
by: Zakiyah N, et al.
Published: (2021-10-01)

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
by: Francesco Cacciatore, et al.
Published: (2020-04-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China
by: Yue Wu, et al.
Published: (2020-07-01)

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
by: Tianyang Hu, et al.
Published: (2023-03-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)

Sacubitril/Valsartan for Heart Failure: Exciting Times but Are Doctors Informed and Ready?
by: Prithwish Banerjee
Published: (2017-01-01)

Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
by: Vanesa Gregorietti, et al.
Published: (2020-11-01)

Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
by: Swathi Pathadka, et al.
Published: (2021-01-01)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01)

Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials
by: Hongzhou Zhang, et al.
Published: (2020-12-01)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
by: Magnus O. Wijkman, et al.
Published: (2022-06-01)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
by: Pema Raj, et al.
Published: (2021-08-01)

Sacubitril/valsartan for heart failure in patients with complex adult congenital heart disease – Experience from a tertiary centre in Singapore
by: Limin Yan, et al.
Published: (2021-12-01)

Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction
by: Z. D. Kobalava, et al.
Published: (2020-12-01)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
by: Ana Martín‐Garcia, et al.
Published: (2020-04-01)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
by: Katie L. Peppin, et al.
Published: (2020-01-01)

Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out‐of‐Pocket Costs
by: Birju R. Rao, et al.
Published: (2023-04-01)

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
by: Diana-Carina Iovanovici, et al.
Published: (2022-09-01)

Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure
by: Marina V. Vitsenya, et al.
Published: (2023-09-01)

Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
by: Amr Abdin, et al.
Published: (2022-12-01)

Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up
by: Carla Paolini, et al.
Published: (2021-08-01)

Cost-Consequence Analysis of Sacubitril/Valsartan versus Enalapril in Chronic Heart Failure Patients with Reduced Ejection Fraction
by: Sameer Bhaskar GOKHALE, et al.
Published: (2021-07-01)

Sacubitril/valsartan in Heart Failure and Beyond—From Molecular Mechanisms to Clinical Relevance
by: Maja Nikolic, et al.
Published: (2022-06-01)

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
by: Alex Heyse, et al.
Published: (2019-12-01)

Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure – A prospective observational study
by: Tahir Saleem Bhat, et al.
Published: (2022-05-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
by: Juan Carlos López‐Azor, et al.
Published: (2019-12-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
by: Juan Jiang, et al.
Published: (2023-03-01)

Reverse Remodeling and Functional Improvement of Left Ventricle in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan: Comparison between Non-Ischemic and Ischemic Etiology
by: Roberto Cemin, et al.
Published: (2023-01-01)

Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
by: Ruoyu Jia, et al.
Published: (2022-11-01)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)

First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy
by: S. G. Kanorskiy, et al.
Published: (2019-10-01)

Sex Differences in the Effectiveness of Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril–Valsartan for the Treatment of Heart Failure
by: Zahra N. Sohani, et al.
Published: (2023-07-01)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
by: Domingo Pascual-Figal, et al.
Published: (2021-11-01)

The protocol and rationale for the efficacy aNd ToleRability of sacUbitril-valSarTan in adult congenital heart disease patients with heart failure (ENTRUST ACHD HF) registry
by: V Appadurai, et al.
Published: (2021-05-01)